Zepbound Outperforms Wegovy in Weight Loss Clinical Trial

(HealthDay News) — Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical trial funded by Lilly. “Given the increased interest around obesity medications, we conducted this study to help health care providers and patients make informed decisions about treatment choice,” Dr. Leonard Glass, senior vice president of global medical affairs at Lilly Cardiometabolic Health, said in an Eli Lilly news release announcing the trial results on Wednesday. “We are thrilled that today’s findings showed the superior weight loss of Zepbound, which helped patients achieve 47% more relative weight loss compared to Wegovy.” In the study, 751 obese and overweight adults across the United States were randomized to get one of the two highest doses of either Zepbound or Wegovy. What did researchers discover? Patients who got weekly injections of Zepbound lost an average of 20.2 percent (50.3 pounds) of their body weight after 72 weeks, compared with an average of 13.7 percent body weight loss (33.1 pounds) for those on Wegovy. While this is the first randomized clinical trial comparing the two rival drugs, the findings haven’t yet been peer-reviewed, the company noted. Earlier research had shown Zepbound outperforms...